Protandim, a Fundamentally New Antioxidant Approach in Chemoprevention Using Mouse Two-Stage Skin Carcinogenesis as a Model by Liu, Jianfeng et al.
Protandim, a Fundamentally New Antioxidant Approach
in Chemoprevention Using Mouse Two-Stage Skin






4, Joe M. McCord
5, Yunfeng Zhao
1*
1Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America,
2Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America, 3Department of Neurosurgery, Louisiana
State University Health Sciences Center, Shreveport, Louisiana, United States of America, 4Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center,
Shreveport, Louisiana, United States of America, 5Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, United States of America
Abstract
Oxidative stress is an important contributor to cancer development. Consistent with that, antioxidant enzymes have been
demonstrated to suppress tumorigenesis when being elevated both in vitro and in vivo, making induction of these enzymes
a more potent approach for cancer prevention. Protandim, a well-defined combination of widely studied medicinal plants,
has been shown to induce superoxide dismutase (SOD) and catalase activities and reduce superoxide generation and lipid
peroxidation in healthy human subjects. To investigate whether Protandim can suppress tumor formation by a dietary
approach, a two-stage mouse skin carcinogenesis study was performed. At the end of the study, the mice on a Protandim-
containing basal diet had similar body weight compared with those on the basal diet, which indicated no overt toxicity by
Protandim. After three weeks on the diets, there was a significant increase in the expression levels of SOD and catalase, in
addition to the increases in SOD activities. Importantly, at the end of the carcinogenesis study, both skin tumor incidence
and multiplicity were reduced in the mice on the Protandim diet by 33% and 57% respectively, compared with those on
basal diet. Biochemical and histological studies revealed that the Protandim diet suppressed tumor promoter-induced
oxidative stress (evidenced by reduction of protein carbonyl levels), cell proliferation (evidenced by reduction of skin
hyperplasia and suppression of PKC/JNK/Jun pathway), and inflammation (evidenced by reduction of ICAM-1/VCAM-1
expression, NF-kB binding activity, and nuclear p65/p50 levels). Overall, induction of antioxidant enzymes by Protandim
may serve as a practical and potent approach for cancer prevention.
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Introduction
Cancer is affected by alterations in multiple physiological events
including apoptosis, inflammation, differentiation, and angiogenesis.
Oxidative stress, resulting from the imbalance between antioxidants
and prooxidants, has been recognized to play an important role in
cancer development. Consistent with that, antioxidant enzymes,
especially superoxide dismutase (SOD), have been demonstrated to
reduce tumorigenesis both in vitro and in vivo [1–2].
SOD not only suppresses cell proliferation, but also affects
inflammation. The association between chronic inflammation and
cancer is now well established [3–7]. One important mechanism of
inflammation-induced cancer is due to oxidative stress [8–11],
which results from the release of free radicals from activated
immune cells and cytokines.
A new approach to antioxidant therapy via the induction of
antioxidant enzymes (including SOD and catalase) has been
developed [12]. The dietary supplement, Protandim, is a
combination of five phytochemicals from medicinal plants long
recorded in traditional Indian and Chinese medicine. One capsule
of Protandim (675 mg) consists of the following: B. monnieri (45%
bacosides), 150 mg; S. marianum (70–80% silymarin), 225mg; W.
somnifera (1.5% withanolides), 150 mg; C. sinensis (98% polyphenols
and 45% (-)-epigallocatechin-3-gallate), 75 mg; and C. longa (95%
curcumin), 75 mg [12]. Protandim has been tested in healthy
human subjects, producing increased SOD and catalase activities
and decreased lipid oxidation levels in the blood samples without
causing overt toxicity [12]. Being a critical step, studies have been
performed to optimize the dosing of Protandim. At the current
dose, none of the five ingredients alone significantly induces
antioxidant enzymes; however, subtraction of any ingredient
significantly reduces the induction. In summary, the bioactivities of
each ingredient form a synergistic effect when combined [13].
In this study, the cancer preventative activity of Protandim is
tested using a well-established two-stage skin carcinogenesis mouse
model. The mouse skin carcinogenesis is a well-developed model
to screen anti-cancer reagents. In this model, a tumor initiator
(e.g., dimethylbenz[a]anthracene [DMBA]) is first treated to cause
mutations of the oncogene Ras. A tumor promoter (e.g., 12-O-
tetradecanoylphorbol-13-acetate [TPA]) is then applied to selec-
tively promote the growth of Ras-mutated skin epidermal cells. As
a phorbor ester, TPA can directly activate protein kinase C [14].
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5284However, low concentrations of TPA can also exert inhibitory
effect on cell proliferation either alone or in combination with anti-
cancer drugs in human pancreas cancer cells [15], and human
prostate cancer cells [16,17]. A phase I dose escalation trial of
TPA has been performed in patients with relapsed or refractory
malignancies and the tolerated dose has been established [18].
Materials and Methods
Animals and treatment
For the two-stage skin carcinogenesis study. Six-to-eight-
week-old female DBA/2 mice were purchased from the Jackson
Laboratory (Indianapolis, IN) and housed in the LSUHSC-S
Animal Resource Facility (four in one cage in microisolators) under
standard regulations. The LSUHSC-S Animal Facility is AAALAC
approved and maintains a consultation team of two veterinarians.
The program is also monitored by the National Institute of Health
Office for Protection from Research Risk and the U.S. Department
of Agriculture. All animals were provided food and water ad
libitum. Animals were euthanized under general anesthesia
(overdose of pentobarbital) at the termination of each study. This
method is consistent with the recommendation by the Panel of
Euthanasia of the American Veterinary Medical Association.
These mice were divided into four groups: Basal diet (AIN-
76A)+vehicle control (DMSO) group (5 mice); Protandim-
containing basal diet+vehicle control group (5 mice); basal
diet+DMBA+TPA group (15 mice); and Protandim-containing
basal diet+DMBA+TPA group (15 mice).
A single dose of 100 nmol dimethylbenz[a]anthracene (DMBA)
(Sigma, St. Louis, MO) dissolved in dimethylsulfoxide (DMSO,
Sigma) was painted on the back of mice. After two weeks, mice
were fed with either Protandim-containing diet (600 mg/kg diet;
Protandim in power form was provided by Dr. Joe McCord) or
basal diet (AIN-76A, both diets were manufactured by Dyets Inc
[Bethlehem, PA]) till the end of the treatment protocol. After
another two weeks, 4 mg of 12-O-tetradecanoylphorbol-13-acetate
(TPA, Sigma), also dissolved in DMSO, was applied to the same
area 5 days per week for 14 weeks. At the end of the treatments,
the mice were euthanized and skin tissues were removed. Non-
tumor skin tissues were carefully collected for biochemical and
histological studies. To monitor the possibility of mycoplasma
infection in the mouse skin tissues, the levels of mycoplasma
pathogens were detected in a variety of tissue lysate (e.g., whole
cell lysate, nuclear extract) using a MycoAlert Mycoplasma
Detection Kit purchased from Lonza (Rockland, ME), and the
results were negative. The remaining tumor-bearing tissues were
fixed in 4% neutral buffered formaldehyde for subsequent
pathological examination, which was performed by Dr. Xin Gu,
a board-certified pathologist at LSUHSC-Shreveport.
For the in vivo SOD induction study. Twenty mice (8–10
weeks old, female, in DBA2 background) were divided into two
groups (ten per group), fed with either basal diet or Protandim diet
for three weeks. The mice were then euthanized, and skin
epidermal tissues were collected. The total cell lysate was prepared
using 50 mM phosphate buffer (pH 7.8), which was used to
measure SOD expression/activity and catalase expression levels.
The data was presented as mean6SD.
Preparation of nuclear extract from skin tissues
At the end of the two-stage skin carcinogenesis study, non-tumor
skin tissues were collected, and skin epidermal cells were stripped off
as previously described [19]. Cells were suspended in 800 mLo f
buffer A (10 mmol/L HEPES-KOH with 1.5 mmol/L MgCl2,
10 mmol/L KCl, 0.2 mmol/L phenylmethylsulfonyl fluoride, and
5 mmol/L DTT) containing protease inhibitors (5 mg/mL each of
pepstatin, leupeptin, and aprotinin), and homogenized in a 10-mL
Wheaton homogenizer. After a short (10-second) spin, the
supernatant was kept on ice for 30 minutes, 25 mL of 10% NP40
was then added, and the sample was vortexed vigorously for
25 seconds. The lysate was centrifuged at 17,0006g for 1 minute.
The resulting pellet was dissolved in 120 mL of buffer B [20 mmol/
L HEPES-KOH with 1.5 mmol/L MgCl2, 420 mmol/L NaCl,
35% glycerol, 0.2 mmol/L phenylmethylsulfonyl fluoride, 5 mMo f
DTT, and 0.2 mmol/L EDTA (pH 8.0)] containing the above
protease inhibitors. The sample was kept on ice for 30 minutes,
followed by centrifugation at 14,0006g for 5 minutes, and the
supernatant, identified as nuclear extract, was frozen at 280uC.
Preparation of whole cell lysate from skin tissue
Skin epidermal cells, stripped from non-tumor tissues, were
extracted by homogenization in 1 mL of Homogenization Buffer
[20 mmol/L HEPES (pH 7.0), 5 mmol/L EGTA, 10 mmol/L 2-
mercaptoethanol, 1 mmol/L phenylmethylsulfonyl fluoride, and
1 mg/mL each of the protein inhibitors mentioned above]. The
lysate was centrifuged (506g or 600 rpm, 5 minutes) to remove
tissuedebris.Theresultingsupernatant wascentrifuged at10,0006g
for 1 hour at 4uC. The supernatant was transferred into a new tube
and designated as whole cell lysate and kept at 280uC.
MnSOD and total SOD activity assays
The MnSOD and total SOD activities were measured using the
NBT-BCS SOD inhibition assay as previously described by Spitz
and Oberley [20]. Total cell lysate was prepared similarly to that
of whole cell lysate except that 50 mM phosphate buffer (pH 7.8,
containing proteinase inhibitors) was used to replace the
Homogenization Buffer. The assay buffer contained xanthine-
xanthine oxidase which generated superoxide; NBT was then
reduced by superoxide to form blue formazan. The presence of
SOD inhibited NBT reduction. The data was plotted as
percentage inhibition vs. protein concentration. One unit of
activity was defined as the amount of protein needed to inhibit
50% of the NBT reduction rate. NaCN (5 mM) was used to
measure MnSOD activity and the CuZnSOD activity was
obtained after subtracting the MnSOD activity from the total
SOD activity. BCS was used to inhibit tissue specific interferences.
Detection of oxidatively modified proteins (protein
carbonyls)
The OxyBlot protein oxidation detection kit (s7150, Intergen,
Purchase, NY) was used to perform the assay. The reaction
procedures were conducted according to the manufacturer’s
instructions. Ten percent SDS-PAGE gels were used for the
separation of whole cell lysate of the stripped skin epidermal cells.
H&E staining of the skin tissues
At the end of the skin carcinogenesis study, 3 small pieces
(approximately 4 mm
3 each) of non-tumor skin tissues were fixed
in 4% neutral buffered formaldehyde for the following histological
studies. Tissue embedding, processing, and Hematoxylin & Eosin
(H&E) staining (to detect skin hyperplasia) were carried out at the
Research Core Laboratory at the Department of Anatomy and
Cell Biology of LSU Health Sciences Center-Shreveport, following
the standard laboratory protocols.
Macrophage staining of the skin tissues
Slides with non-staining tissues were deparafinized followed by
antigen retrieval using a steamer. The slides were then pre-treated
Protandim in Cancer Prevention
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serum. A rat anti-mouse F4/80 antibody (Invitrogen, Carlsbad,
CA; 1:100 dillution in 5% normal serum) was used to stain
macrophages, and rat serum was used for blocking. The samples
were then stained using an ABC staining system following the
procedures provided by the manufacturer (Santa Cruz). Finally,
the samples were counterstained with hematoxylin. Graphs were
randomly taken from the stained slides using a Zeiss Axiophot
photomicroscope (amplification: 206).
Electrophoretic mobility shift assays (EMSAs)
Nuclear factor-kB (NF-kB)-DNA binding activity was analyzed
using nuclear extract. The NF-kB double-strand oligonucleotide (59-
AGTTGAGGGGACTTTCCCAGGC-39) was purchased from
Promega (Madison, WI). The 25-ml reaction solution contained
6 mgo fnuclear extract,5mlo f5 6binding buffer (50 mM Tris-HCl,
pH 7.4, with 20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 5 mM
DTT, and 0.25 mg/ml poly dI-dC) and 50,000 cpm labeled
probe. After 20 minutes of incubation at room temperature, 3 ml
of 106loading buffer was added, and samples were separated on a
6% native polyacrylamide gel for 3 to 4 hours. The gel was dried
and DNA-protein complexes were visualized by exposing the gel
to a Kodak film at 280uC. A supershift assay was performed in a
separate gel, following the procedures similarly to what has been
described [21] with slight modifications [22]. The anti-p65 or p50
antibodies for supershift (106, purchased from Santa Cruz) were
incubated with nuclear extract for 1 h at room temperature before addition of
the labeled probe.
Western Blot analysis
Whole cell lysate was used to detect the expression levels of
(p)PKCe, JNK, pJNK, ICAM-1, VCAM-1, and GAPDH. Nuclear
extract were used to detect the expression levels of Jun D, Fra-1,
NFkB subunit p65 and p50, and Lamin B. Twenty micrograms of
whole cell lysate or 5 micrograms of nuclear extract was separated on a
10% SDS-PAGE gel and transferred onto a PVDF membrane.
Ponceau S staining was used to monitor uniform transfer of
protein. All primary and secondary antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). The antibody
bands were visualized by the enhanced chemiluminescence
detection system (ECL, Amersham Pharmacia Biotech, Piscat-
away, NJ). The membranes were then stripped and reprobed with
an anti-GAPDH or anti-Lamin B antibody to normalize protein
loading. The corresponding bands were scanned, and the density
was quantitatively assessed using VersaDoc Imaging System
equipped with QuantityOne Software (Bio-Rad, Hercules, CA).
There were five tissues samples in each group and the Western
blot results were semi-quantitatively analyzed as the following: the
density of each band of interest was divided by the density of the
corresponding loading control band. For comparisons, the Basal
diet/Vehicle was set up as the control group, and the ratios were
calculated based on this group.
Statistical analysis
Statistical analysis was performed using both a Student’s t-Test
(with two-tailed distribution and two-sample equal variance) (for
two-group comparison) and one-way ANOVA (for multiple-group
comparison) followed by the Newman-Keuls post-test. p,0.05 was
judged to be significantly different.
Results
Protandim diet suppressed skin tumor formation
We first tested whether the Protandim diet suppresses tumor
formation in a two-stage skin carcinogenesis model. At the end of
the study, no significant difference in the body weight between the
basal diet group (Basal diet/DMBA+TPA, n=15) and the
Protandim diet group (Protandim/DMBA+TPA, n=15) indicated
no overt toxicity (26.561.3 g vs 26.061.0 g, p=1.3). The
pathological examination is summarized in Table 1. The results
show that there was no tumor formation in the two (basal diet and
Protandim diet) vehicle control groups. In the two DMBA+TPA
treatment groups, 100% of the mice from the basal diet group
developed tumors, and the average number of tumors per mouse
in this group was 6.3. Only 66.7% of the mice from the Protandim
diet group developed tumors, and the average number of tumors
per mouse was 2.7. These results revealed that the Protandim diet
reduced tumor incidence by 33% and multiplicity by 57%
(p=0.003).
Protandim diet suppressed TPA-induced cell proliferation
Skin epidermal hyperplasia was revealed in H&E stained tissues.
As shown in Figure 1A, TPA treatment induced cutaneous hyper-
proliferation in the basal diet group, whereas Protandim diet
reduced the levels of hyperplasia.
To detect the effect of the Protandim diet on the signaling
molecules contributing to tumor promotion, non-tumor tissues
were collected at the end of the skin carcinogenesis study, and
Western blot analysis was performed. As the important oncopro-
teins and subunits of the transcription factor - activator protein- 1
(AP-1) in skin carcinogenesis, Jun and Fos family members have
been previously studied [23]. The results demonstrate that Jun D
and Fra-I make major contributions to AP-1 binding activity [23].
As summarized in Figure 1B, in the samples from the basal diet
group, TPA treatment induced a 2.8-fold increase in Jun D
expression and a 2.5-fold increase in Fra-1 expression in the
nucleus, compared to a 1.7-fold increase in Jun D and a 1.6-fold
increase in Fra-1 in the Protandim diet group. The expression
levels of phosphorylated c-Jun N-Terminal Kinase (pJNK) were
next examined using whole cell lysate. Also in Figure 1B, in the
samples from the basal diet group, TPA treatment induced a 2.3-
Table 1. Papilloma formation in the multistage carcinogenesis model.
Treatment Number of Mice Tumor Incidence Papillomas/mouse Total Papillomas
Basal diet/TPA 15 100% 6.363.3 94
Protandim/TPA 15 66.7% 2.762.7* 40
Basal diet/Vehicle 5 0% 0600
Protandim/Vehicle 5 0% 0600
*p=0.003 compared with the basal diet/TPA group. Vehicle: DMSO.
doi:10.1371/journal.pone.0005284.t001
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of JNK), compared to a 1.4-fold increase in the Protandim diet
group. Protandim diet alone did not affect either Jun D/Fra-1 or
pJNK level significantly.
Protandim diet suppressed TPA-induced cutaneous
inflammation
TPA is known to incite cutaneous inflammation, which further
contributes to skin tumor formation [24–25]. To investigate
whether the Protandim diet modulates cutaneous inflammation as
a mechanism of its tumor suppressive effects, the same set of tissues
from the cell proliferation study was also used for the following
study.
Immunohistochemical examination of infiltrated macrophage
was first detected in the skin tissues. As shown in Figure 2A, in
vehicle (DMSO) treated mice, whether on Basal diet or Protandim
diet, few macrophages were observed in the mouse skin tissues.
There were increased infiltrated macrophages in TPA-treated
Basal diet group; whereas less macrophages were observed in
TPA-treated Protandim diet group.
Western blot analysis was performed to detect the expression of
ICAM-1 and VCAM-1 in skin epidermal cells using whole cell lysate.
As shown in Figure 2B, both ICAM-1 and VCAM-1 levels were
significantly increased (2-fold) upon TPA treatment in the samples
from the basal diet group. These increases were significantly
reduced in the samples from the Protanidm diet group.
NF-kB is a pivotal regulator of proinflammatory gene
expression [26]. The NF-kB–DNA binding activity was detected
using EMSA. As shown in Figure 2C, TPA treatment induced
increases in NF-kB–DNA binding activity in the samples from the
basal diet group, whereas these increases were reduced in samples
from the Protandim diet group. The expression levels of p65 and
p50, as two subunits of NF-kB, were also detected using nuclear
extract (Figure 2D). Consistent with the increases in NF-kB binding
activity, the protein levels of the two subunits were also increased
upon TPA treatment in the samples from the basal diet group, and
these increases were reduced in the Protandim diet group.
Protandim diet induced superoxide dismutase (SOD) and
catalase, leading to suppression of oxidative stress in skin
epidermal tissues
Protandim is designed to induce primary antioxidant enzymes,
which was first demonstrated in healthy human subjects [12]. In
order to determine whether the Protandim diet could induce SOD
expression/activity and catalase expression in skin epidermal
tissues within a short period of time, animals were fed with either
of the two diets for three weeks. Total cell lysate from the collected
skin epidermal tissues was used to detect the SOD expression/
activity levels, and the results are summarized in Figure 3. In
detail, there was a 35% increase in total SOD activity and a 21%
increase in MnSOD activity in the Protandim diet group
(Figure 3A), which is consistent with the results seen in the human
studies [12]. The increases in SOD activities are likely caused by
the induction of protein expression, since there was a 37% increase
in MnSOD and a 23% increase in CuZnSOD expression levels
(Figure 3B). The expression levels of catalase were also detected,
and there was a 58% increase in the Protandim diet group
(Figure 3C).
Finally the levels of protein carbonyls, as an oxidative stress
marker, were detected. As shown in Figure 3D, TPA treatment
induced increases in the oxidatively modified proteins at the
molecular weight 54, 42, and 27 kd in the samples from the basal
diet group. These increases were reduced in samples from the
Protandim diet group.
Discussion
Oxidative stress plays a positive role during cancer develop-
ment. Overexpression of antioxidant enzymes, especially manga-
nese superoxide dismutase (MnSOD), has been demonstrated to
suppress tumorigenesis when being elevated both in vitro and in vivo
[2]. To seek a more practical antioxidant approach which can be
used for dietary based chemoprevention, Protandim, a combina-
tion of five medicinal plants has been developed and a preliminary
test in humans has been performed [12]. Each ingredient of
Protandim has shown antioxidant activities (Bacoside [27];
silymarin [28]; W. somnifera powder [29]; green tea [30];
curcumin [31]). However, the combination of ingredients creates
a synergistic effect and lowers the concentration of each ingredient
in the induction of Nrf2-regulated antioxidant enzymes [13].
While CuZnSOD, MnSOD, and catalase are probably not
directly upregulated by Nrf2 (as they do not appear to contain
Antioxidant Response Elements in their promoters), they have
been reported to be included in the array of enzymes induced by
Nrf2 activators. MnSOD, e.g., has been shown to behave like
heme oxygenase-1 and glutamate cysteine ligase (both of which are
directly Nrf2-regulated) with regard to silencing of Nrf2 via siRNA
knockdown studies [32]. One possible mechanism for ‘‘secondary’’
induction of MnSOD by Nrf2 activation is the upregulation and
nuclear translocation of thioredoxin by Nrf2 [33]. Thioredoxin,
itself, is a transcription factor that has been shown to induce
MnSOD [34].
We first tested the chemo-preventative effect of Protandim using
a well-developed skin carcinogenesis mouse model. The human
dose of Protandim of 675 mg/d is approximately 10 mg/kg/d. A
20-g mouse should receive nearly 2.5 mg/d to receive an
equivalent dose, according to the equation established by
Reagan-Shaw et al [35]. The amount of Protandim per kg chow
we used (600 mg/kg) delivers almost exactly 2.5 mg of Protandim
if the mouse eats a little over 4 g of chow per day. So we chose a
dose equivalent to the human dose (taking one Protandim caplet
per day). Within three weeks, SOD activity/expression levels were
induced by Protandim diet. The increased level in MnSOD
activity (21%) is less than that in MnSOD expression (37%). This
might be due to the interaction between MnSOD and p53, which
leads to inactivation of MnSOD activity, as previous studies have
demonstrated [36]. Protandim is a combination of five ingredients
designed to induce SOD and catalase. It is likely that this
combination will also induce many additional antioxidant enzymes
Figure 1. Detection of cell proliferation markers contributing to skin carcinogenesis. Samples were collected at the end of the skin
carcinogenesis study (n=5 per group). Data was reported as means6standard error (SEM), and p,0.05 was judged to be significantly different. *,
significantly different from the basal diet/Vehicle group; #, significantly different from the basal diet/TPA group. Vehicle: DMSO. (A) H&E staining of
skin epidermal tissues. A representative result was shown. Arrows point to the layer of skin epidermis. The histologic evaluation was conducted by a
pathologist (X.G.) who had no knowledge of the treatments. The number of skin epidermal layers was plotted and statistical analysis was performed
using one-way ANOVA followed by the Newman-Keuls post-test. (B) Semi-quantitative analysis of the protein levels of pJNK, Jun D, and Fra-1. Vehicle:
DMSO. The levels of pJNK were normalized to that of JNK, and the levels of Jun D and Fra-1 were normalized to that of Lamin B. Statistical analysis
was performed using one-way ANOVA (for multiple-group comparison) followed by Newman-Keuls post-test.
doi:10.1371/journal.pone.0005284.g001
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recently been shown that Protandim causes the translocation of
Nrf2 to the nucleus [13]. Indeed, the expression levels of heme
oxygenase-1 (HO-1, data not shown) were also increased in the
same set of samples for SOD detection. MnSOD became the
major interest for this study, based on the previous skin
carcinogenesis studies which show that only overexpression of
MnSOD suppresses skin tumor formation, but not overexpression
of CuZnSOD [37], nor glutathione peroxidase [37]. To our
knowledge, no studies using HO-1 or catalase overexpression mice
in skin carcinogenesis have been reported.
Oxidative stress contributes to multiple physiological events
including cell proliferation and inflammation, mediated by
modifying redox sensitive AP-1 (proliferation) and NF-kB (inflam-
mation) pathways. The nature of mitogen (e.g. TPA)-induced
inflammation includes the generation of superoxide radicals.
Superoxide radicals could serve as signaling molecules to induce
cell proliferation. TPA can also directly bind to PKC; members of
the PKC family regulate downstream of nearly all membrane-
associated signal transduction pathways. In addition to promoting
cell proliferation, in PKCa-overexpressed primary keratinocytes,
NF-kB is a pivotal regulator of proinflammatory gene expression
[25]. Furthermore, TNFa is PKC-inducible when overexpressed in
mouse keratinocytes, and is highly induced in PKC transgenic skin
[38]. These studies clearly demonstrate that cell proliferation and
inflammation can indeed interact during skin carcinogenesis. Since
the NF-kB pathway has an essential role in adaptive response and
cell survival [39], increasing evidence suggests that deregulation of
NF-kB and its regulatory kinases play a contributing role to cancer
development, progression, and resistance to chemotherapy [40–41].
Thereafter, developing inhibitors of the NF-kB pathway might
potentiate the therapeutic effects of chemo drugs, through the
mechanism of enhancing cell death [42]. Such efforts have been
illustrated in a recent study by Bauer et al. [43], the authors showed
enhanced drug efficacy using nitrosylcobalamin, which inhibits NF-
kB activation and its survival signaling.
Figure 2. Detection of cutanous inflammation markers. Samples were collected at the end of the skin carcinogenesis study (n=5 per group).
(A) Immunohistochemical staining of macrophages in mouse skin tissues. The skin samples were prepared at the end of the two-stage carcinogenesis
study. The arrows (in red) indicate macrophage staining. Amplification: 206. (B) Semi-quantitative analysis of the protein levels of ICAM-1 and VCAM-
1. The levels of ICAM-1/VCAM-1 were normalized to that of GAPDH. Statistical analysis was performed using one-way ANOVA (for multiple-group
comparison) followed by Newman-Keuls post-test. Data was reported as means6standard error (SEM), and p,0.05 was judged to be significantly
different. *, significantly different from the basal diet/Vehicle group; #, significantly different from the basal diet/TPA group. Vehicle: DMSO. (C)
Electrophoretic mobility shift analysis of NF-kB-DNA binding activity. A representative result was shown. The specific bands were quantified and
plotted, and statistical analysis was performed using one-way ANOVA. For the supershift experiment, either anti-p65 or anti-p50 antibody (both are
concentrated antibodies) was preincubated with nuclear axtract for 1 h at room temperature before addition of the labeled probe. The Basal diet/TPA
samples were chosen for the assay. Vehicle: DMSO. (D) Western blot analysis of the nuclear levels of p65 and p50. Lamin B served as the loading
control. A representative result was shown. The p65/p50 bands were quantified and normalized to the corresponding Lamin B bands. Statistical
analysis was performed using one-way ANOVA. Vehicle: DMSO.
doi:10.1371/journal.pone.0005284.g002
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effects and other activities. Bacosides, a traditional Ayurvedic
medicine, has been used in India for centuries as a memory
enhancing, anti-inflammatory, analgesic, antipyretic, sedative and
antiepileptic agent [44]. Silymarin is known as a hepatoprotectant,
but also shows anti-cancer and cytoprotective activities on organs
including the prostate, lungs, CNS, kidneys, pancreas and skin [45].
W. somnifera has shown anti-angiogenesis and anti-cancer activities
[46–47]. Green tea (EGCG) shows promising results in cancer
prevention and treatment in a large number of studies [48–52].
Curcumin is another rising star as a cancer prevention agent [53–
56]. However, the benefits of forming this combination include: 1)
existing a synergistic effect; and 2) lowering the concentration of
each ingredient to reduce the potential side effects.
In summary, tumor promoter TPA incites cutaneous prolifer-
ation and inflammation mediated at least in part, by oxidative
stress. Protandim prevents skin tumor formation via the induction
of several primary antioxidant enzymes. As the induction of
antioxidant enzymes is a much more potent approach than
supplementation with conventional stoichiometric antioxidants,
Protandim may be suitable for translational research and may
serve as a therapeutic approach for cancer prevention.
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Figure 3. Detection of oxidative stress and antioxidant enzymes in skin epidermal tissues. For Figure 3A to 3C, skin tissues from the
three-week dietary supplementation study were used (n=10 per group). Statistical analysis was performed using Student’s t-test. Data was reported
as means6standard deviation (SD), and p,0.05 was judged to be significantly different. *, significantly different from the basal diet group. For
Figure 3D, skin tissues from the two-stage skin carcinogenesis study were chosen (n=5 per group). (A) Total SOD and MnSOD activity. For the total
SOD activity, the numbers were 150.3622.3 (mean6S.D.) vs 202.8641.0, and p=0.0039. For the MnSOD activity, the numbers were 77.769.8 vs
94.3620.1, and p=0.039. (B) Semi-quantitative analysis of the protein levels of MnSOD and CuZnSOD. (C) Semi-quantitative analysis of the protein
levels of catalase. (D) Detection of oxidatively modified proteins. A representative result was shown. All of the carbonyl-modified bands in each lane
were quantified, combined, and normalized to GAPDH. Statistical analysis was performed using one-way ANOVA (for multiple-group comparison)
followed by Newman-Keuls post-test. Data was reported as means6standard error (SEM), and p,0.05 was judged to be significantly different. *,
significantly different from the basal diet/Vehicle group; #, significantly different from the basal diet/TPA group. Vehicle: DMSO.
doi:10.1371/journal.pone.0005284.g003
Protandim in Cancer Prevention
PLoS ONE | www.plosone.org 7 April 2009 | Volume 4 | Issue 4 | e5284References
1. Oberley LW, Buettner GR (1979) Role of superoxide dismutase in cancer: a
review. Cancer Res 39: 1141–1149, review.
2. Oberley LW (2005) Mechanism of the tumor suppressive effect of MnSOD
overexpression. Biomed Pharmacother 59: 143–148, review.
3. Apte RN, Dotan S, Elkabets M, White MR, Reich E, et al. (2006) The
involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-
host interactions. Cancer Metastasis Rev 25: 387–408, review.
4. Fox JG, Wang TC (2007) Inflammation, atrophy, and gastric cancer. J Clin
Invest 117: 60–69, review.
5. Marks F, Furstenberger G, Muller-Decker K (2007) Tumor promotion as a
target of cancer prevention. Recent Results Cancer Res 174: 37–47, review.
6. Pries R, Nitsch S, Wollenberg B (2006) Role of cytokines in head and neck
squamous cell carcinoma. Expert Rev Anticancer Ther 6: 1195–1203, review.
7. Rose-John S, Schooltink H (2007) Cytokines are a therapeutic target for the
prevention of inflammation-induced cancers. Recent Results Cancer Res 174:
57–66, review.
8. Ballaz S, Mulshine JL (2003) The potential contributions of chronic
inflammation to lung carcinogenesis. Clin Lung Cancer 5: 46–62, review.
9. Farrow B, Evers BM (2002) Inflammation and the development of pancreatic
cancer. Surg Oncol 10: 153–169, review.
10. Halliwell B (2007) Oxidative stress and cancer: have we moved forward?
Biochem J 401: 1–11, review.
11. Seril DN, Liao J, Yang GY, Yang CS (2003) Oxidative stress and ulcerative
colitis-associated carcinogenesis: studies in humans and animal models.
Carcinogenesis 24: 353–362, review.
12. Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM (2006) The
induction of human superoxide dismutase and catalase in vivo: a fundamentally
new approach to antioxidant therapy. Free Radic Biol Med 40: 341–347.
13. Velmurugan K, Alam J, McCord JM, Pugazhenthi S (2009) Synergistic
induction of heme oxygenase-1 by the components of the dietary supplement
Protandim. Free Radic Biol Med 46: 430–440.
14. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, et al. (1982) Direct
activation of calcium-activated, phospholipid-dependent protein kinase by
tumor-promoting phorbol esters. J Biol Chem 257: 7847–7851.
15. Avila GE, Zheng X, Cui XX, Ryan AD, Hansson A, et al. (2005) Inhibitory
effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with
all-trans retinoic acid on the growth of cultured human pancreas cancer cells and
pancreas tumor xenografts in immunodeficient mice. J Pharmacol Exp Ther
315: 170–187.
16. Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, et al. (2006) Effects of 12-
O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel
(Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft
tumors in immunodeficient mice. Clin Cancer Res 12: 3444–3451.
17. Zhang X, Li W, Olumi AF (2007) Low-dose 12-O-tetradecanoylphorbol-13-
acetate enhances tumor necrosis factor related apoptosis-inducing ligand
induced apoptosis in prostate cancer cells. Clin Cancer Res 13: 7181–7190.
18. Schaar D, Goodell L, Aisner J, Cui XX, Han ZT, et al. (2006) A phase I clinical
trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed/
refractory malignancies. Cancer Chemother Pharmacol 57: 789–795.
19. Zhao Y, St Clair DK (2003) Detection of the content and activity of the
transcription factor AP-1 in a multistage skin carcinogenesis model. Methods
Mol Biol 218: 177–184.
20. Oberley LW, Spitz DR (1984) Assay of superoxide dismutase activity in tumor
tissue. Methods Enzymol 105: 457–464.
21. DiDonato JA (2000) Assaying for I kappa B kinase activity. Methods Enzymol
322: 393–400.
22. Zhao Y, Kiningham KK, Lin SM, St. Clair DK (2001) Overexpression of
MnSOD protects murine fibrosarcoma cells (FSa-II) from apoptosis and
promotes a differentiation program upon treatment with 5-Azacytidine:
involvement of MAPK and NFkappaB pathways. Antioxid Redox Signal 3:
375–386.
23. Zhao Y, Xue Y, Oberley TD, Kiningham KK, Lin SM, et al. (2001)
Overexpression of manganese superoxide dismutase suppresses tumor formation
by modulation of activator protein-1 signaling in a multistage skin carcinogenesis
model. Cancer Res 61: 6082–6088.
24. Fujisawa H, Naito Y, Horiuchi S, Baba T, Otsuka F (1992) The effects of
interferon-beta on phorbol ester or calcium ionophore-induced intercellular
adhesion molecule-I expression in epidermal carcinoma cells. J Dermatol 19:
78–81.
25. Dressler J, Bachmann L, Strejc P, Koch R, Muller E (2000) Expression of
adhesion molecules in skin wounds: diagnostic value in legal medicine. Forensic
Sci Int 113: 173–176.
26. Cataisson C, Pearson AJ, Torgerson S, Nedospasov SA, Yuspa SH (2005)
Protein kinase C alpha-mediated chemotaxis of neutrophils requires NF-kappa B
activity but is independent of TNF alpha signaling in mouse skin in vivo.
J Immunol 174: 1686–1692.
27. Chowdhuri DK, Parmar D, Kakkar P, Shukla R, Seth PK, et al. (2002)
Antistress effects of bacosides of Bacopa monnieri: modulation of Hsp70
expression, superoxide dismutase and cytochrome P450 activity in rat brain.
Phytother Res 16: 639–645.
28. Soto C, Recoba R, Barron H, Alvarez C, Favari L (2003) Silymarin increases
antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp
Biochem Physiol C Toxicol Pharmacol 136: 205–212.
29. Chaurasia SS, Panda S, Kar A (2000) Withania somnifera root extract in the
regulation of lead-induced oxidative damage in male mouse. Pharmacol Res 41:
663–666.
30. Das M, Sur P, Gomes A, Vedasiromoni JR, Ganguly DK (2002) Inhibition of
tumour growth and inflammation by consumption of tea. Phytother Res. pp
S40–44.
31. Dikshit M, Rastogi L, Shukla R, Srimal RC (1995) Prevention of ischaemia-
induced biochemical changes by curcumin & quinidine in the cat heart.
Indian J Med Res 101: 31–35.
32. Na HK, Kim EH, Jung JH, Lee HH, Hyun JW, et al. (2008) (-)-Epigallocatechin
gallate induces Nrf2-mediated-antioxidant enzyme expression via activation of
PI3K and ERK in human mammary epithelial cells. Arch Biochem Biophys
476: 171–177.
33. Jakubikova J, Sedlak J, Bod’o J, Bao Y (2006) Effect of isothiocyanates on
nuclear accumulation of NF-kappaB, Nrf2, and thioredoxin in caco-2 cells.
J Agric Food Chem 54: 1656–1662.
34. Das KC, Lewis-Molock Y, White CW (1997) Elevation of manganese superoxide
dismutase gene expression by thioredoxin. Am J Respir Cell Mol Biol 17:
713–726.
35. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to
human studies revisited. FASEB J 22: 659–661.
36. Zhao Y, Chaiswing L, Velez JM, Batinic-Haberle I, Colburn NH, et al. (2005)
p53 translocation to mitochondria precedes its nuclear translocation and targets
mitochondrial oxidative defense protein-manganese superoxide dismutase.
Cancer Res 65: 3745–3750.
37. Lu YP, Lou YR, Yen P, Newmark HL, Mirochnitchenko OI, et al. (1997)
Enhanced skin carcinogenesis in transgenic mice with high expression of
glutathione peroxidase or both glutathione peroxidase and superoxide
dismutase. Cancer Res 57: 1468–1474.
38. Ruckert R, Lindner G, Bulfone-Paus S, Paus R (2000) High-dose proin-
flammatory cytokines induce apoptosis of hair bulb keratinocytes in vivo.
Br J Dermatol 143: 1036–1039.
39. Luo JL, Kamata H, Karin M (2005) IKK/NF-kappaB signaling: balancing life
and death–a new approach to cancer therapy. J Clin Invest 115: 2625–2632.
Review.
40. Israe ¨l A (2003) Signal transduction: A regulator branches out. Nature 423:
596–597.
41. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes
and pitfalls. Nat Rev Drug Discov 8: 33–40. Review.
42. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to
anticancer drugs. Nat Rev Cancer 5: 297–309.
43. Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, et al. (2007)
Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic
agents via suppression of survival signaling. PLoS ONE 2: e1313.
44. Russo A, Borrelli F (2005) Bacopa monniera, a reputed nootropic plant: an
overview. Phytomedicine 12: 305–317, review.
45. Gazak R, Walterova D, Kren V (2007) Silybin and silymarin–new and emerging
applications in medicine. Curr Med Chem 14: 315–338, review.
46. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG (2003) Growth inhibition of
human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci
74: 125–132.
47. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, et al.
(2004) Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7:
115–122.
48. Clark J, You M (2006) Chemoprevention of lung cancer by tea. Mol Nutr Food
Res 50: 144–151, review.
49. Fujiki H (2005) Green tea: Health benefits as cancer preventive for humans.
Chem Rec 5: 119–132, review.
50. Hoshiyama Y, Kawaguchi T, Miura Y, Mizoue T, Tokui N, et al. (2005) JACC
Study Group. Green tea and stomach cancer–a short review of prospective
studies. J Epidemiol Suppl 2: S109–112, review.
51. Stuart EC, Scandlyn MJ, Rosengren RJ (2006) Role of epigallocatechin gallate
(EGCG) in the treatment of breast and prostate cancer. Life Sci 79: 2329–2336,
review.
52. Wright TI, Spencer JM, Flowers FP (2006) Chemoprevention of nonmelanoma
skin cancer. J Am Acad Dermatol 54: 933–946, review.
53. Narayanan BA (2006) Chemopreventive agents alters global gene expression
pattern: predicting their mode of action and targets. Curr Cancer Drug Targets
6: 711–727, review.
54. Sharma RA, Gescher AJ, Steward WP (2005) Curcumin: the story so far.
Eur J Cancer 41: 1955–1968, review.
55. Singh RP, Agarwal R (2006) Mechanisms of action of novel agents for prostate
cancer chemoprevention. Endocr Relat Cancer 13: 751–778, review.
56. Singh S, Khar A (2006) Biological effects of curcumin and its role in cancer
chemoprevention and therapy. Anticancer Agents Med Chem 6: 259–270,
review.
Protandim in Cancer Prevention
PLoS ONE | www.plosone.org 8 April 2009 | Volume 4 | Issue 4 | e5284